



HAL
open science

Early and Reliable Detection of Herpes Simplex Virus Type 1 and Varicella Zoster Virus DNAs in Oral Fluid of Patients with Idiopathic Peripheral Facial Nerve Palsy: Decision Support Regarding Antiviral Treatment?

Andreas Lackner, Harald H Kessler, Christian Walch, Stefan Quasthoff,
Reinhard B Raggam

► To cite this version:

Andreas Lackner, Harald H Kessler, Christian Walch, Stefan Quasthoff, Reinhard B Raggam. Early and Reliable Detection of Herpes Simplex Virus Type 1 and Varicella Zoster Virus DNAs in Oral Fluid of Patients with Idiopathic Peripheral Facial Nerve Palsy: Decision Support Regarding Antiviral Treatment?. *Journal of Medical Virology*, 2010, 82 (9), pp.1582. 10.1002/jmv.21849 . hal-00556037

HAL Id: hal-00556037

<https://hal.science/hal-00556037>

Submitted on 15 Jan 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Early and Reliable Detection of Herpes Simplex Virus Type 1 and Varicella Zoster Virus DNAs in Oral Fluid of Patients with Idiopathic Peripheral Facial Nerve Palsy: Decision Support Regarding Antiviral Treatment?

Journal:	<i>Journal of Medical Virology</i>
Manuscript ID:	JMV-10-1732.R2
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	13-Apr-2010
Complete List of Authors:	Lackner, Andreas Kessler, Harald Walch, Christian Quasthoff, Stefan Raggam, Reinhard; Medical University of Graz, Clinical Institute of Medical and Chemical Laboratory Diagnostics
Keywords:	Bell's palsy , Varicella zoster virus, Herpes simplex virus , Oral fluid, real time PCR



1
2
3 1 **Early and Reliable Detection of Herpes Simplex Virus Type 1 and**
4
5
6 2 **Varicella Zoster Virus DNAs in Oral Fluid of Patients with Idiopathic**
7
8
9 3 **Peripheral Facial Nerve Palsy: Decision Support Regarding Antiviral**
10
11 4 **Treatment?**
12
13
14 5

16 6 Andreas Lackner,^{a#} Harald H. Kessler,^b Christian Walch^a, Stefan
17
18
19 7 Quasthoff,^c and Reinhard B. Raggam,^{d*#}
20
21
22 8
23
24 9
25

26
27 10 ^a Department of Neurotology, Medical University of Graz, Austria
28

29 11 ^b Research Unit Molecular Diagnostics, IHMEM, Medical University of Graz, Austria
30

31 12 ^c Department of Neurology, Medical University of Graz, Austria
32

33
34 13 ^d Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical
35
36 14 University of Graz, Austria
37
38
39 15
40
41 16
42
43 17
44

45
46 18 *Corresponding author at: Clinical Institute of Medical and Chemical Laboratory
47
48 19 Diagnostics, Medical University of Graz, 8036 Graz, Austria; Phone: +43 316 385
49
50 20 80243; Fax: +43 316 385 13430; E-mail: reinhard.raggam@medunigraz.at
51
52

53 21
54
55 22 # Authors contributed equally to this work.
56
57 23
58
59 24

60 Running head: HSV-1 and VZV in Oral Fluid of Patients with Bell's Palsy

ABSTRACT

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 Idiopathic peripheral facial nerve palsy has been associated with the reactivation of
3 herpes simplex virus type 1 (HSV-1) or varicella zoster virus (VZV). In recent studies,
4 detection rates were found to vary strongly which may be caused by the use of
5 different oral fluid collection devices in combination with molecular assays lacking
6 standardization. In this single-center pilot study, liquid phase-based and absorption
7 based oral fluid collection was compared. Samples were collected with both systems
8 from 10 patients with acute idiopathic peripheral facial nerve palsy, 10 with herpes
9 labialis or with Ramsay Hunt Syndrome, and 10 healthy controls. Commercially
10 available IVD/CE labeled molecular assays based on fully automated DNA extraction
11 and real-time PCR were employed. With the liquid phase-based oral fluid collection
12 system, 3 patients with idiopathic peripheral facial nerve palsy tested positive for
13 HSV-1 DNA and another 2 tested positive for VZV DNA. All patients with herpes
14 labialis tested positive for HSV-1 DNA and all patients with Ramsay Hunt Syndrome
15 tested positive for VZV DNA. With the absorption based oral fluid collection system,
16 detections rates and viral loads were found to be significantly lower when compared
17 to those obtained with the liquid phase-based collection system. Collection of oral
18 fluid with a liquid phase-based system and the use of automated and standardized
19 molecular methods allow early and reliable detection of HSV-1 and VZV DNAs in
20 patients with acute idiopathic peripheral facial nerve palsy and may provide a
21 valuable decision support regarding start of antiviral treatment at the first clinical visit.

22
23 **KEYWORDS:** Bell's palsy; herpes simplex virus; varicella zoster virus; oral fluid; real
24 time PCR

INTRODUCTION

The idiopathic peripheral facial nerve palsy also referred as “Bell’s Palsy” is a diagnosis of exclusion [Finsterer, 2008]. The reactivation of herpes simplex virus type 1 (HSV-1) or varicella zoster virus (VZV) has been suggested to be among the etiologies of idiopathic peripheral facial nerve palsy [Burgess et al., 1994; Furuta et al., 2001; Abiko et al., 2002; Furuta et al., 2004; Lazarini et al., 2006; Yamakawa et al., 2006; Lockhart et al., 2009]. Antiviral treatment for patients with idiopathic peripheral facial nerve palsy has been discussed controversially [Adour, 1994; Ahmed, 2005; Hato et al., 2007; Kawaguchi et al., 2007; Hato et al., 2008; Lockhart et al., 2009]. Reported detection rates for HSV-1 and VZV differ significantly. This may be due to the use of non standardized oral fluid collection or absorption based oral fluid collection devices in conjunction with homebrew molecular assays lacking internal controls in those studies.

In this pilot study, liquid phase-based and absorption based oral fluid collection was compared. Oral fluid samples were collected from patients with acute idiopathic peripheral facial nerve palsy, those with herpes labialis, those with Ramsay Hunt Syndrome, and healthy controls with both oral fluid collection systems. HSV-1 DNA and VZV DNAs were detected by in vitro diagnosis (IVD/Conformité Européenne (CE)) labeled molecular assays based on fully automated sample preparation and real-time PCR. Detection rates and viral loads were compared in order of the oral fluid collection systems used.

METHODS

Study Population and Collection of Oral Fluid Samples

A total of 10 patients (3 females, 7 males; mean age, 44 years; age range, 29 to 77 years) suffering from acute idiopathic peripheral facial nerve palsy were enrolled and assigned as study group. Five patients with visible herpes labialis (3 females, 2 males; mean age, 28 years; age range, 18 to 51 years) and 5 patients with acute Ramsay Hunt Syndrome (3 females, 2 males; mean age, 58 years; age range, 37 to 76 years) served as positive control groups. Ten healthy subjects (6 females, 4 males; mean age, 28 years; age range, 23 to 39) years lacking IgM antibodies against both HSV and VZV and without clinical presentation compatible to infection produced by HSV and VZV served as negative controls. None of the patients and healthy controls showed any immunodeficiency. No corticosteroids and/or antiviral treatment were administered within 4 weeks before enrolment. This pilot study was approved by the ethical committee of the Medical University of Graz. All study participants gave written informed consent.

Idiopathic peripheral facial nerve palsy was diagnosed according to general investigation guidelines and the grade of palsy was determined according to the a grading scale described by House and Brackmann [1985] and Ahmed [2005].

Whole blood, cerebrospinal fluid (CSF) and oral fluid samples were collected within the first 4 days of onset of clinical symptoms. For collecting oral fluid, two different collection systems, the liquid phase-based Saliva Collection System (SCS; Greiner Bio-One GmbH, Kremsmünster, Austria) and the absorption based Salivette[®] (Sarstedt GmbH, Nümbrecht, Germany) were used according to the manufacturers' instructions. In all patients, oral fluid was collected with the absorption based system first, followed by the use of the liquid phase-based system.

Antibody Testing

Serum and CSF testing for IgM and IgG antibodies against neurotropic viruses including HSV, VZV, Coxsackie A and B, and *Borrelia burgdorferi* was done by using commercially available ELISA tests (Institut Virion/Serion GmbH, Würzburg, Germany) on the BEP III instrument (Siemens Healthcare Diagnostics GmbH, Eschborn, Germany).

Molecular Assays

Molecular assays for detection of HSV-1 DNA and VZV DNA in oral fluid were based on automated DNA extraction and real-time PCR as reported recently [Raggam et al., 2008]. For automated DNA extraction on the MagNA Pure Compact instrument (Roche Applied Science, Penzberg, Germany), the MagNA Pure Compact Nucleic Acid Isolation Kit I (Roche) was employed. For quantitative real-time PCR on the IVD-LightCycler 2.0 instrument (Roche), commercially available CE-labeled assays, the artus[®] HSV-1/2 LC PCR Kit (Qiagen, Hilden, Germany) and the artus[®] VZV LC PCR Kit (Qiagen) were employed according to the instructions of the manufacturer. The lower limit of detection of both the HSV-1/2 and the VZV assay is 250 copies/ml.

RESULTS

In this pilot study, a total of 30 study participants were included. None of the 10 idiopathic peripheral facial nerve palsy patients included showed IgM antibodies for neurotropic viruses and *Borrelia burgdorferi* in serum and in CSF. When collected with the liquid phase-based SCS, oral fluid samples of 3 idiopathic peripheral facial nerve palsy patients tested positive for HSV-1 DNA and that of another 2 idiopathic peripheral facial nerve palsy patients tested positive for VZV DNA. For the corresponding oral fluid samples collected with the absorption based Salivette[®], positive results for HSV-1 DNA were identical but showing distinctly lower viral copy numbers when compared to oral fluid samples having been collected with the liquid phase-based system. VZV DNA was not detectable in any of the 10 investigated oral fluid samples having been collected with the absorption based system (Table I).

When oral fluid samples were collected with the liquid phase-based SCS from 5 patients with herpes labialis, all were positive for HSV-1 DNA; when collected with the absorption based Salivette[®] only 3 of 5 patients were positive with distinctly lower viral copy numbers (Table II). When oral fluid samples were collected from patients with Ramsay Hunt Syndrome, all of them tested positive for VZV DNA with the liquid phase-based SCS and 4 of 5 patients were positive when collected with the absorption based Salivette[®] showing also distinctly lower viral copy numbers (Table II). All 10 healthy controls were negative for both viral DNAs tested.

DISCUSSION

The etiopathogenesis of idiopathic peripheral facial nerve palsy is uncertain; acute immune demyelination triggered by a viral infection may be responsible since viral shedding into the oral cavity was reported recently [Furuta et al., 1998; Singhi and Jain, 2003].

There is no consensus regarding treatment options. Clinical trials investigating the efficacy of specific antiviral treatment did not show a significant benefit in comparison to alternative treatment [Adour, 1994; Ahmed, 2005; Hato et al., 2007; Kawaguchi et al, 2007; Hato et al., 2008; Lockhart et al., 2009]. However, these treatment-based trials did not consider the possible presence of HSV-1 and VZV DNAs in oral fluid of idiopathic peripheral facial nerve palsy patients as inclusion criterion; furthermore, non automated homebrew assays for detection of viral DNAs lacking internal controls were used. In addition, neuroborreliosis as a possible cause of facial paralysis was not excluded in recent studies [Ahmed, 2005; Hato et al., 2007; Kawaguchi et al, 2007; Hato et al., 2008; Lockhart et al., 2009].

In this pilot study, IVD/CE labeled molecular assays based on an automated DNA extraction and real-time PCR were employed. A possible systemic neurotropic virus infection and the existence of Lyme neuroborreliosis were excluded.

All patients included in this study suffered from acute idiopathic peripheral facial nerve palsy and had not received corticosteroids and/or antiviral treatment within 4 weeks prior to admission to hospital. Oral fluid samples were obtained within the first 4 days of onset of clinical symptoms. This is of importance because the prevalence of viral DNAs has been reported to be highest during the acute phase of the disease due to extensive viral shedding into the oral cavity [Singhi and Jain, 2003]. Oral fluid samples from 5 patients with herpes labialis and from 5 patients with Ramsay Hunt

1
2
3 1 Syndrome served as positive controls for HSV-1 DNA and VZV DNA detection in
4
5
6 2 collected oral fluid samples, respectively.

7
8 3 When the liquid-phase based oral fluid collection system was used, viral DNAs
9
10 4 were detected in 5 patients with acute idiopathic peripheral facial nerve palsy.
11
12 5 Considering the small sample size of this study, the detection rate (50%) of viral
13
14 6 DNAs in oral fluid obtained from idiopathic peripheral facial nerve palsy patients was
15
16 7 found to be higher compared to those found in other studies [Burgess et al., 1994;
17
18 8 Furuta et al., 2001; Abiko et al., 2002, Furuta et al., 2004; Lazarini et al., 2006;
19
20 9 Yamakawa et al., 2006; Hato et al., 2007; Kawaguchi et al., 2007; Hato et al., 2008;
21
22 10 Lockhart et al., 2009]. When the oral fluid collection systems were compared in the
23
24 11 idiopathic peripheral facial nerve palsy group, positive results for HSV-1 DNA were
25
26 12 identical but oral fluid samples collected with the absorption based system showed
27
28 13 up to $3x_{log}$ lower viral copy numbers. Detection of VZV DNA in oral fluid samples of
29
30 14 these patients was only possible with the liquid-phase based oral fluid collection
31
32 15 system. The obtained results for VZV DNA showed viral copy numbers close to the
33
34 16 lower limit of detection of the molecular assay, suggesting that liquid phase-based
35
36 17 oral fluid collection may be superior when only a small amount of viral DNA is present.
37
38 18 This may indicate a matrix-dependent lower yield of viral nucleic acids when
39
40 19 absorption based oral fluid collection is used. Similar effects were also observed in
41
42 20 the two control groups where oral fluid samples collected with the absorption based
43
44 21 collection system gave negative results for both viral DNAs while low-positive results
45
46 22 could be observed in corresponding oral fluid samples collected with the liquid
47
48 23 phase-based oral fluid collection system.

49
50
51 24 In conclusion, both collection of oral fluid with a liquid-phase based system and
52
53 25 the use of automated molecular methods allow early and reliable detection of HSV-1
54
55 26 and VZV DNAs in oral fluid samples collected from patients with acute idiopathic

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 peripheral facial nerve palsy. This information may offer a valuable decision support
2 for clinicians regarding start of antiviral treatment at the first clinical visit since
3 sampling is non-invasive, quick and easy to handle and automated standardized
4 molecular assays have a short turnaround time. A major limitation of this pilot study is
5 the small samples size. To verify these findings, a multicenter study including a
6 greater number of patients with idiopathic peripheral facial palsy should be performed.

7

For Peer Review

ACKNOWLEDGEMENTS

The authors gratefully acknowledge Michael Bozic for technical assistance, Lisa Daghofer and Dietmar Leichtfried for stimulating discussions.

CONFLICT OF INTEREST STATEMENT

The authors declare that they have no conflict of interests.

For Peer Review

REFERENCES

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 1
2 Abiko Y, Ikeda M, Hondo R. 2002. Secretion and dynamics of herpes simplex virus in
3 tears and saliva of patients with Bell's palsy. *Otol Neurotol* 23:779–783.
4 Adour KK. 1994. Otolological complications of herpes zoster. *Neurology* 35:62-64.
5 Ahmed A. 2005. When is facial paralysis Bell palsy? Current diagnosis and
6 treatment. *Cleve Clin J Med* 72:398-401.
7 Burgess RC, Michaels L, Bale JF, Smith RJH. 1994. Polymerase Chain Reaction
8 amplification of herpes simplex viral DNA from the geniculate ganglion of a patient
9 with Bell's palsy. *Ann Otol Rhinol Laryngol* 3:775-779.
10 Finsterer J. 2008. Management of peripheral facial nerve palsy. *Eur Arch*
11 *Otorhinolaryngol* 265:743–752.
12 Furuta Y, Fukuda S, Chida E, Takasu T, Ohtani F, Inuyama Y, Nagashima K. 1998.
13 Reactivation of herpes simplex virus type 1 in patients with Bell's palsy. *J Med*
14 *Virology* 54:162-166.
15 Furuta Y, Ohtani F, Sawa H, Fukuda S, Inuyama Y. 2001. Quantitation of varicella-
16 zoster virus DNA in patients with ramsay hunt syndrome and zoster sine herpette.
17 *J Clin Microbiol* 39:2856–2859.
18 Furuta Y, Aizawa H, Ohtani F, Sawa H, Fukuda S. 2004. Varicella-zoster virus DNA
19 level and facial paralysis in Ramsay Hunt syndrome. *Ann Otol Rhinol Laryngol*
20 113:700-705.
21 Hato N, Yamada H, Kohno H, Matsumoto S, Honda N, Gyo K, Fukuda S, Furuta Y,
22 Ohtani F, Aizawa H, Aoyagi M, Inamura H, Nakashima T, Nakata S, Murakami S,
23 Kiguchi J, Yamano K, Takeda T, Hamada M, Yamakawa K. 2007. Valacyclovir
24 and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo-
25 controlled study. *Otol Neurotol* 28:408-413.

- 1
2
3 1 Hato N, Sawai N, Teraoka M, Wakisaka H, Takahashi H, Hinohira Y, Gyo K. 2008.
4
5 2 Valacyclovir for the treatment of Bell's palsy. *Expert Opin Pharmacother* 9:2531-
6
7 2536.
8
9
10 4 House JW, Brackmann DE. 1985. Facial nerve grading system. *Otolaryngol Head*
11
12 *Neck Surg* 93:146-147.
13
14
15 6 Kawaguchi K, Inamura H, Abe Y, Kosu H, Takashita E, Muraki Y, Matsuzaki Y,
16
17 7 Nishimura H, Ishikawa H, Fukao A, Hongo S, Aoyagi M. 2007. Reactivation of
18
19 8 herpes simplex virus type 1 and varicella-zoster virus and therapeutic effects of
20
21 9 combination therapy with prednisolone and valacyclovir in patients with Bell's
22
23 10 palsy. *Laryngoscope* 117:147-156.
24
25
26
27 11 Lazarini PR, Vianna MF, Alcantara MP, Scalia RA, Caiaffa Filho HH. 2006. Herpes
28
29 12 simplex virus in the saliva of peripheral Bell's palsy patients. *Braz J*
30
31 13 *Otorhinolaryngol* 72:7-11.
32
33
34 14 Lockhart P, Daly F, Pitkehly M, Comerford N, Sullivan F. 2009. Antiviral treatment for
35
36 15 Bell's palsy (idiopathic facial paralysis). *Cochrane Database of Systematic*
37
38 16 *Reviews Issue 4*. Art. No.: CD001869. Doi; 10.1002/14651858.CD001869.pub4.
39
40
41 17 Raggam RB, Wagner J, Michelin BD, Putz-Bankuti C, Lackner A, Bozic M, Stauber E,
42
43 18 Santner BI, Marth E, Kessler HH. 2008. Reliable detection and quantitation of
44
45 19 viral nucleic acids in oral fluid: Liquid phase-based sample collection in
46
47 20 conjunction with automated and standardized molecular assays. *J Med Virol*
48
49 21 80:1684-1688.
50
51
52
53 22 Singhi P, Jain V. 2003. Bell's palsy in children. *Semin Pediatr Neurol* 10:289-297.
54
55 23 Yamakawa T, Hamada M, Takeda T. 2006. Different real-time PCR assays could
56
57 24 lead to a different result of detection of varicella zoster virus in facial palsy. *J Virol*
58
59 25 *Methods* 139:227-229.
60

TABLE I. Detection Rates and Viral Loads of HSV-1 DNA and VZV DNA in Oral Fluids Collected from idiopathic peripheral facial nerve palsy Patients Using Two Different Collection Systems, the Liquid Phase-Based SCS and the Absorption Based Salivette®.

Patient no.	Oral Fluid samples collected with:			
	Liquid phase-based SCS		Absorption based Salivette®	
	No. of HSV-1 DNA copies/ml	No. of VZV DNA copies/ml	No. of HSV-1 DNA copies/ml	No. of VZV DNA copies/ml
1	TND ^a	2.5 x 10 ³	TND	TND
2	TND	TND	TND	TND
3	3.5 x 10 ⁵	TND	2.9 x 10 ²	TND
4	TND	TND	TND	TND
5	2.0 x 10 ⁵	TND	6.6 x 10 ³	TND
6	TND	TND	TND	TND
7	TND	TND	TND	TND
8	TND	2.6 x 10 ²	TND	TND
9	1.4 x 10 ⁵	TND	2.5 x 10 ³	TND
10	TND	TND	TND	TND

^aTarget Not Detected.

TABLE II. Detection Rates and Viral Loads of HSV-1 DNA and VZV DNA in Oral Fluids Collected from Patients with herpes labialis and from Patients with Ramsay Hunt Syndrome Using Two Different Collection Systems, the Liquid Phase-Based SCS and the Absorption Based Salivette®.

	Oral Fluid samples collected with:			
	Liquid phase-based SCS		Absorption based Salivette®	
	No. of HSV-1 DNA copies/ml	No. of VZV DNA copies/ml	No. of HSV-1 DNA copies/ml	No. of VZV DNA copies/ml
Patients with herpes labialis	9.2×10^2	TND ^a	TND	TND
	8.8×10^4	TND	1.5×10^3	TND
	2.6×10^4	TND	1.7×10^3	TND
	5.3×10^4	TND	3.8×10^3	TND
	7.4×10^4	TND	TND	TND
Patients with Ramsay Hunt Syndrome	TND	6.5×10^3	TND	TND
	TND	7.0×10^6	TND	8.8×10^4
	TND	1.7×10^5	TND	2.1×10^3
	TND	2.5×10^5	TND	2.5×10^3
	TND	3.8×10^5	TND	4.0×10^3

^aTND, Target Not Detected.